Meta Information

ID:sglt2-inhibitors

Name:SGLT2 Inhibitors

Schema Version:1.5

Title

SGLT2 Inhibitors

Alternate Names

• Gliflozins

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

50

High Cost:

500

Cost Type:

monthly

Description:

Varies widely based on insurance coverage and availability of generic versions.

Summary

SGLT2 inhibitors are a class of prescription drugs that block glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine. This lowers blood sugar, promotes a mild state of ketosis, and reduces blood pressure, mimicking some of the metabolic effects of caloric restriction. Their proven cardiovascular and renal protective benefits, even in non-diabetics, make them a significant intervention for healthspan.

Purpose

Lowers blood glucose and mimics fasting for metabolic health.

Card Summary

A class of diabetes drugs that lowers blood glucose by excretion, mimicking some metabolic benefits of fasting and providing robust organ protection.

Drug Class

Drugs In Class

• canagliflozin
• dapagliflozin
• empagliflozin
• ertugliflozin

Impact

Score:

7.5

Justification:

Strong evidence for cardiovascular and renal protection beyond simple glucose lowering.

Evidence

Grade:

A

Score:

9

Justification:

Multiple large-scale human RCTs show significant cardiovascular and renal benefits.

Safety

Score:

5.5

Justification:

Prescription drug with risks of UTIs, yeast infections, and rare ketoacidosis.

Flags

• Requires a prescription and ongoing medical supervision.
• Increased risk of urinary tract and genital yeast infections due to glucosuria.
• Carries a rare but serious risk of euglycemic ketoacidosis (eKA), especially with low-carb diets or illness.
• May cause dehydration or hypotension; adequate hydration is crucial.
• Interacts with diuretics and may require dose adjustments for insulin or sulfonylureas.

Verdict

High-impact metabolic intervention with robust evidence but requires medical supervision.

Created

2026-04-24T00:10:22.185124Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

oral

Scope:

• systemic

Indication

Focus:

disease_treatment

Description:

SGLT2 inhibitors are a class of prescription drugs that block glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine. This lowers blood sugar, promotes a mild state of ket...

Typical Protocol

• Daily low-dose empagliflozin (10mg) or canagliflozin (100mg) is a common off-label approach.